Notice of Intent to Sole Source Lease of Avatar Odyssey Instruments

This is a Notice of Intent, not a request for quotations. A solicitation will not be issued, and quotations will not be requested. This notice is for informational purposes only. The Department of Health and Human Services (HHS), National Institutes of Health (NIH), Clinical Center (CC), on behalf of the Center for Cellular Engineering (CCE), intends to award a firm-fixed-price contract on a sole source basis to: Xcell Biosciences, Inc. 455 Mission Bay Blvd Suite 124 San Francisco, California 94158-2159 Requirement: The purpose of this acquisition is to lease four (4) Avatar™ Odyssey instruments for a period of six (6) months to support process development activities within the CCE laboratories located at the NIH Clinical Center, Bethesda, Maryland. These instruments enable precise control of cellular microenvironment conditions, including oxygen tension (hypoxia to normoxia), pressure, and temperature, which are critical for evaluating and optimizing cell therapy manufacturing processes. The Center for Cellular Engineering develops and manufactures investigational cell-based therapies for patients with limited or no remaining standard treatment options, in compliance with Current Good Manufacturing Practice (cGMP)

requirements (21 CFR Parts 210, 211, 600, and 1271). Although the instruments are designated for research use only and will not be used for clinical manufacturing, they are essential for generating data that will inform process optimization, improve cell phenotype and function, and support future acquisition of GMP-compliant systems. Authority: FAR 13.106-1(b)(1) – Soliciting from a single source when only one source is reasonably available. Justification for Sole Source: Market research conducted by the Government determined that Xcell Biosciences, Inc. is the only responsible source capable of providing the required Avatar™ Odyssey system. The Avatar Odyssey platform is the only commercially available system that integrates programmable control of both oxygen tension and pressure within a single system suitable for cell therapy process development. No other vendors were identified that can meet these

requirements or provide data that is transferable to future GMP-compliant systems.

Period of Performance: Six (6) months from date of award

Place of Performance: National Institutes of Health Clinical Center 10 Center Drive Bethesda, MD 20892 Response Information: Interested parties may submit a capability statement demonstrating their ability to meet this requirement. Responses must be received within 10 calendar days of this notice.

Point of Contact: Team Leader: Shasheshe Goolsby Email: shasheshe.goolsby@nih (OALM) Disclaimer: This notice is not a request for competitive quotes. Shasheshe Goolsby Contracting ., SUITE 503L (No Street Address